Press releases

March 2021

SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version

SynAct Pharma AB ("SynAct") today announced that dosing in the second part of the exploratory clinical Phase 2 study with AP1189 in Covid-19 patients conducted under the RESOVIR collaboration has been... Read more

SynAct Pharma’s CFO and board member sell shares to cover taxes on holdings

SynAct Pharma AB (“SynAct”) today announced that board member John Haurum has sold 5,968 shares and Chief Financial Officer Henrik Stage has sold 57,000 shares in SynAct Pharma. The sales correspond to ... Read more

February 2021

Year-end Report 2020

2020-10-01 – 2020-12-31 (fourth quarter) Consolidated net sales amounted to TSEK 0 (0). The Group's profit before tax amounted to TSEK -9 786 (-11 203). The Group's earnings per share amounted to SEK -... Read more

SynAct Pharma Names James Knight as Chief Business Officer – Already published in Swedish today

SynAct Pharma AB (“SynAct”) today announced the appointment of James Knight as Chief Business Officer (CBO). He will head up business development and pipeline portfolio management and has more than 25 ... Read more

SynAct carries out a directed share issue and raises proceeds of SEK 80 million

SynAct Pharma AB (publ) (”SynAct” or ”the Company”) has, in accordance with the announcement made in a press release yesterday, successfully completed a directed share issue of 1,600,000 shares at a pr... Read more

SynAct explores the conditions for carrying out a directed share issue – English version – Published today 17.31 CET

SynAct Pharma AB (publ) (“SynAct” or “the Company”) has engaged ABG Sundal Collier AB to explore the conditions for carrying out a directed share issue of up to SEK 55 million based on an accelerated bookbui... Read more

SynAct Pharma prepares move to Nasdaq Stockholm – English version – Published today at 17.31 CET

February 4, 2021 17:31 CET The Board of Directors of SynAct Pharma AB (“SynAct Pharma” or the “Company”) has decided to evaluate the conditions and begin preparing for listing the Company’s share on ... Read more

January 2021

SynAct Pharma names Thomas Boesen as Chief Operating Officer

SynAct Pharma AB (“SynAct”) today announced the appointment of Dr. Thomas Boesen as Chief Operating Officer (COO), effective immediately. His operational role as the new COO will be to drive forward the... Read more

Published in English – already published 11:18 CET today Disclosure notice in SynAct Pharma AB

SynAct Pharma AB (“SynAct” or the “Company”) hereby announces that the Company’s shareholders TJ Biotech ApS (wholly-owned by the board member and CSO Thomas Jonassen) and Quantass ApS (owned by the CE... Read more